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ABSTRACT
Background: The “comparison of triflusal and clopidogrel effects in secondary prevention 
of stroke based on cytochrome P450 2C19 (CYP2C19) genotyping (MAESTRO)” study was a 
prospective, multicenter, randomized, open-label, and blind genotype trial. We performed 
a subgroup analysis of the MAESTRO study to explore the relationship between VerifyNow 
P2Y12 assay with regard to CYP2C19 polymorphisms and smoking status in patients with 
non-cardiogenic ischemic stroke who underwent clopidogrel treatment.
Methods: For the study, patients treated with clopidogrel and who underwent VerifyNow 
P2Y12 assay was selected from the MAESTRO study.
Results: Of the 393 patients in 18 hospitals, 256 (65%) patients in 12 hospitals were entered 
for this subgroup analysis. P2Y12 reaction unit (PRU) was significantly lower and percent 
inhibition (% INH) was higher in the current smoking group than in the nonsmoking group 
(p<0.001). The same results were also observed in the good genotype group when compared 
with the poor genotype group (p<0.001). Among the groups, significant lower PRU and 
higher % INH was demonstrated in current smoking with good genotype group. However, 
there was no difference in PRU and % INH between current smoking with poor genotype 
group and nonsmoking with good genotype group, suggesting that clopidogrel activity was 
concurrently related to CYP2C19 polymorphisms and smoking status.
Conclusions: Regarding secondary stroke prevention, patients who were current smokers 
and had a poor genotype for clopidogrel metabolism may benefit from clopidogrel treatment 
similar to that in patients who were nonsmokers and had a good genotype.
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INTRODUCTION
The “comparison of triflusal and clopidogrel effects in secondary prevention of stroke based 
on cytochrome P450 2C19 (CYP2C19) genotyping (MAESTRO)” study was a prospective, 
multicenter, randomized, open-label, and blind genotype trial.1) It was designed to compare 
the efficacy and safety of antiplatelet agents for the secondary prevention of ischemic stroke 
based on CYP2C19 polymorphisms. The major finding of the MAESTRO study was that in 
the clopidogrel treatment group, a good CYP2C19 genotype for clopidogrel metabolism was 
associated with a 31% decrease in the relative risk of recurrent stroke. A 41% decrease in the 
relative risk of recurrent ischemic stroke in the good CYP2C19 genotype group was observed, 
although these values were bounded by a wide confidence interval.
Several studies have shown that cigarette smoking could influence the antiplatelet effect of 
clopidogrel by affecting the activity of the cytochrome P450 (CYP) system.2)3) Clopidogrel 
requires oxidation by the hepatic CYP system to generate the active metabolite and CYP2C19 
plays a major role in the metabolism of clopidogrel.4) In the “Clopidogrel in High-risk patients 
with Acute Nondisabling Cerebrovascular Events” trial, a smoking–clopidogrel paradox was 
observed among patients with a recent minor stroke or transient ischemic attack.5) Compared 
with nonsmokers, smokers treated with clopidogrel had secondary stroke prevention at 90 
days from clopidogrel treatment. Recently, it has also been shown that enhanced clopidogrel 
response in smokers is not a universal effect but is rather dependent on genotype status.6)
The VerifyNow P2Y12 assay is a whole blood optical detection test based on the measurement 
of the increase in light transmission. It is intended to directly measure the effects of 
clopidogrel on the P2Y12 receptor and to overcome the limitations of the conventional optical 
platelet aggregation assay.7) The outcomes are expressed as P2Y12 reaction unit (PRU) and 
percent inhibition (% INH), with high PRU and low % INH indicating clopidogrel resistance 
(CR).8) There is emerging evidence pertaining to the relationship between CR and functional 
outcome, stroke recurrence, and mortality following ischemic stroke. However, there is 
no evidence as yet, based on VerifyNow assay in relation to CYP2C19 polymorphisms and 
smoking status, that CR is more clinically informative at predicting recurrent vascular events 
after ischemic stroke.9)10)
In this context, we performed a subgroup analysis of the MAESTRO study to explore the 
relationship between VerifyNow P2Y12 assay with regard to CYP2C19 polymorphisms and smoking 
status in patients with non-cardiogenic ischemic stroke who underwent clopidogrel treatment.
METHODS
The design and method of the MAESTRO study have been published previously.11) Briefly, 
patients were eligible if they were 20 years of age or older and had their first non-cardiogenic 
ischemic stroke. In the clopidogrel treatment group, patients received 75 mg clopidogrel once 
daily. All patients received appropriate medical treatments at the discretion of the attending 
neurologist, including anti-hypertensive treatment, statin treatment, and rigorous control of 
vascular risk factors.
CYP2C19 genotype status was assessed using the Seeplex CYP2C19 ACE Genotyping system 
(Seegene, Seoul, Korea) and Real-Q CYP2C19 genotyping kit (Biosewoom, Seoul, Korea). 
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Patients were classified as ultrarapid metabolizer (UM; *1/*17, *17/*17), extensive metabolizer 
(EM; *1/*1), intermediate (IM)/unknown metabolizer (*1/*2, *1/*3 and *2/*17, *3/*17), or 
poor metabolizer (PM; *2/*2, *2/*3, *3/*3) based on CYP2C19 genotype status. For the study, 
patients with UM or EM status were allocated into the good genotype group for clopidogrel 
metabolism, and patients with IM/unknown metabolizer or PM status were allocated into the 
poor genotype group.1)
CR was tested using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA). Blood 
samples were obtained from patients 2 and 12 weeks after study enrollment. All patients 
received 75 mg clopidogrel once daily for at least 7 consecutive days before testing. The assay 
was performed according to the manufacturer's instructions. In the P2Y12 assay, % INH was 
calculated for each patient as follows: % INH = ([baseline PRU − post-drug PRU] ÷ baseline 
PRU) × 100. The PRU specifies the amount of ADP P2Y12 platelet receptor-mediated platelet 
aggregation and is inversely related to the antiplatelet function.8) If the PRU is low, % INH and 
antiplatelet activity increased. Current smokers were defined as those who smoked regularly 
during the past month. Nonsmokers were defined as those who never smoked or patients who 
stopped smoking for >1 month before enrollment. All patients provided written informed 
consent prior to participation in the study. The study design was approved by the appropriate 
ethics review board and conducted in accordance with the Good Clinical Practice guidelines 
and the Declaration of Helsinki. The study protocol was approved by the Institutional Review 
Board of each participating hospital (Gangnam Severance Hospital, No. 3-2009-0192).
Statistical analyses
Variables were tested for normality using the Kolmogorov–Smirnov test. The baseline 
parameters of each group were analyzed using 1-way ANOVA with a Tukey's post hoc test 
for continuous variables, where appropriate. Univariate analyses of demographics, vascular 
risk factors, and medical history were performed using an independent sample t-test or 
the Mann–Whitney U test for continuous variables and the χ2 test for categorical variables. 
Pearson's and Spearman's correlation coefficients were calculated to evaluate the correlations 
of PRU and % INH with demographics and vascular risk factors. Descriptive data were 
expressed as numbers (percent) or mean±standard deviation. Statistical analyses were 
performed using SPSS version 25.0 for Windows (IBM, Armonk, NY, USA).
RESULTS
A total of 784 patients were included in the MAESTRO study. Clopidogrel was administered 
to 393 patients (50%). Of the 393 patients in 18 hospitals, 256 (65%) patients in 12 hospitals 
were entered for this subgroup analysis. The median duration of follow-up was 3.0 years 
(range, 0–4.5). Table 1 shows the baseline characteristics of enrolled patients. The mean 
age was 61 years, and 29% of the patients were women. Fifty-four percent of patients had a 
history of hypertension, 25% had diabetes, 24% had dyslipidemia, and 38% were current 
tobacco smokers. The most frequent genotype in all patients was IM (118, 46%), followed by 
EM (91, 35%), PM (42, 16%), UM (3, 2%), and unknown (2, 1%). Accordingly, 94 (37%) had 
a good genotype for clopidogrel metabolism and 162 (63%) had a poor genotype. Current 
smoking patients, who were younger men, had higher hemoglobin and hematocrit levels 
and lower hypertension and antihypertensive use rates than those for nonsmoking patients, 
likely related to the differences in habits by gender and age (Table 1). There were no other 
significant differences in the demographics and clinical findings among the groups.
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The results of the VerifyNow P2Y12 assay among the groups are presented in Table 2. PRU 
was significantly lower and % INH was higher in the current smoking group than in the 
nonsmoking group (p<0.001). The same results were also observed in the good genotype 
group when compared with the poor genotype group (p<0.001). Smoking status adjusted 
partial correlation analysis showed that CYP2C19 polymorphisms were related to PRU 
and % INH in patients with non-cardiogenic ischemic stroke who underwent clopidogrel 
treatment (r=0.371, p<0.0001). CYP2C19 polymorphisms adjusted partial correlation 
analysis demonstrated that smoking status was related to PRU and % INH as well (r=0.197, 
p=0.002). Among the groups, significant lower PRU and higher % INH was demonstrated 
in current smoking with good genotype group. However, there was no difference in PRU 
and % INH between current smoking with poor genotype group and nonsmoking with good 
genotype group, suggesting that clopidogrel activity was concurrently related to CYP2C19 
polymorphisms and smoking status (Figure 1).
DISCUSSION
In this study, we investigated the relationship between VerifyNow P2Y12 assay with regard 
to CYP2C19 polymorphisms and smoking status in patients with non-cardiogenic ischemic 
stroke. There was no significant difference in PRU and % INH between current smoking with 
poor genotype group and nonsmoking with good genotype group. Our study clearly showed 
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Table 1. Baseline demographics and characteristics of the participants
Genotype Total (n=256) Current smoking (n=98, 38%) Nonsmoking (n=158, 62%) p value
Good (n=37, 15%) Poor (n=61, 24%) Good (n=57, 22%) Poor (n=101, 39%)
Age (years) 61.0±11.1 57.8±11.2 57.1±10.9 63.8±9.5 63.0±11.4 0.005*
Female (sex) 74 (29) 1 (3) 2 (3) 23 (40) 48 (48) 0.001*
Hypertension 137 (54) 10 (27) 34 (56) 35 (61) 58 (57) 0.006*
Diabetes mellitus 63 (25) 7 (19) 17 (28) 14 (25) 25 (25) 0.802
Hypercholesterolemia 61 (24) 7 (19) 14 (23) 15 (26) 25 (25) 0.859
Ischemic heart disease 7 (3) 1 (3) 1 (2) 2 (4) 3 (3) 0.935
Hemoglobin (g/dL) 13.9±1.7 14.5±1.6 14.5±1.5 13.6±1.5 13.5±1.7 0.001*
Hematocrit (%) 40.9±4.5 42.6±4.3 42.6±4.2 40.0±4.2 39.8±4.4 0.001*
Platelet count (103/mm3) 237.0±55.2 233.0±39.7 246.0±54.8 237.0±57.3 233.0±59.1 0.470
Stroke classification 0.293
LAA 52 (20) 4 (11) 17 (28) 11 (19) 20 (20)
Lacune 136 (53) 22 (59) 32 (52) 26 (46) 56 (55)
SUDn 68 (27) 11 (30) 12 (20) 20 (35) 25 (25)
Use of antihypertensive at any follow-up visit 166 (65) 17 (46) 38 (62) 42 (74) 69 (68) 0.037*
Use of statin at any follow-up visit 224 (88) 33 (89) 47 (77) 52 (91) 92 (91) 0.064
Data are number (% of total participants) or mean±standard deviation.
LAA, large artery atherosclerosis; SUDn, stroke of undetermined etiology.
*Significant p is marked.
Table 2. Clopidogrel PRU and % INH according to smoking status and CYP2C19 genotyping
Genotype Total (n=256) Current smoking (n=98) Nonsmoking (n=158) p value
Good Poor Good Poor
2 weeks
PRU 215.0±77.0 163.0±68.9 215.0±60.6 185.0±74.8 248.0±74.6 0.001*
% INH 32.0±21.0 43.0±22.6 33.0±14.1 40.0±21.9 23.0±19.3 0.001*
12 weeks
PRU 226.0±67.0 195.0±61.1 216.0±43.9 209.0±75.6 249.0±69.0 0.001*
% INH 28.0±17.2 39.0±15.7 27.0±14.7 34.0±20.1 24.0±15.5 0.001*
CYP2C19, cytochrome P450 2C19; % INH, percent inhibition; PRU, P2Y12 reaction unit.
*Significant p is marked.
that responsiveness to the platelet P2Y12 receptor antagonist clopidogrel was related to 
both CYP2C19 polymorphisms and smoking status. Smoking status modified the results of 
VerifyNow P2Y12 assay according to the CYP2C19 polymorphisms.
Factors associated with clopidogrel response variability include clinical and genetic 
variables.10)12) The clinical factors consist of age, smoking, inflammation, diabetes, high body 
mass index, renal failure, and heart failure. Previous studies have shown that the various 
platelet function test systems detect different aspects of platelet activation and may be 
affected by different factors to a variable degree.12) Of these test systems, VerifyNow P2Y12 
assay is a whole blood point-of-care test. Similar to light transmission aggregometry, the 
VerifyNow P2Y12 assay registers the increase of light transmittance through the sample 
after addition of ADP and converts this increase into the extent of platelet aggregation.13) 
The advantages of this assay include full automation, good reproducibility, use of whole 
blood, and small blood volume requirement.10) While a meta-analysis showed that the 
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Figure 1. Clopidogrel PRU and % INH according to smoking status and CYP2C19 genotyping. Among the groups, significant lower PRU and higher % INH is 
demonstrated in current smoking with good genotype group. However, there are no difference in PRU and % INH between current smoking with poor genotype 
group and nonsmoking with good genotype group, suggesting that clopidogrel activity is concurrently related to CYP2C19 polymorphisms and smoking status. 
CYP2C19, cytochrome P450 2C19; % INH, percent inhibition; PRU, P2Y12 reaction unit.
VerifyNow P2Y12 assay is a useful tool for predicting cardiovascular events in patients treated 
with clopidogrel, altering antiplatelet therapy based on VerifyNow P2Y12 assay has not been 
shown to improve vascular outcomes in patients with coronary artery disease (CAD).14)15) There 
is also little evidence from VerifyNow P2Y12 assay in relation to CYP2C19 polymorphisms 
that CR is more clinically informative at predicting recurrent vascular events during follow-
up after ischemic stroke.9) Owing to the diverse etiology of ischemic stroke, data on ex vivo 
platelet function test from CAD patients cannot be extrapolated to those with ischemic stroke. 
Regarding cigarette smoking, several studies have shown enhanced pharmacodynamics effect 
of the platelet P2Y12 receptor antagonist clopidogrel in smokers, a phenomenon known as 
the “smoker's paradox.”16) It has been postulated that smoking is an inducer of clopidogrel 
metabolism by inducing CYP1A2 activity, resulting in low platelet aggregation with clopidogrel 
treatment.5)17) A meta-analysis demonstrated that current smokers have increased platelet 
inhibition and lower aggregation in response to clopidogrel than that in nonsmokers.16) 
However, smoking is an important independent risk factor for recurrent stroke.18)19) Our study 
revealed that although there was no significant difference between smokers and nonsmokers, 
current smokers had a higher number of major vascular events (10.2% vs. 3.4%, p=0.402). 
Rather than encourage smoking, it is important to recognize nonsmokers as a greater risk 
of having a poor antiplatelet response from the clopidogrel treatment. We believe that it is 
reasonable to recommend patients with ischemic stroke to stop cigarette smoking.
The strengths of this study are the long-term follow-up and good medication adherence 
among the patients. The median duration of follow-up was 3.0 years and the patients had 
>80% medication adherence during the trial. VerifyNow P2Y12 assay was performed on the 
same patients 2 and 12 weeks after study enrollment. It may have the potential to provide 
more clinically meaningful information than that from a traditional cross-sectional single 
test. There are several limitations to this study, the first and most important of which is that 
the sample size for this subgroup analysis was small and was not determined a priori. During 
the trial, a total of 13 (5%) patients had recurrent stroke: 10 (77%) experienced an ischemic 
stroke and 3 (23%) experienced an intracerebral hemorrhage. There was no significant 
reduction in the risk of recurrent stroke or a major vascular event among the groups 
(p>0.358). Second, clopidogrel response may be affected by several clinical factors. Owing to 
the small number of vascular outcomes, we could not evaluate clinical factors associated with 
clopidogrel response variability. Finally, this study enrolled only Korean patients, limiting 
the generalizability of our findings to other geographic regions. These limitations should be 
considered during the interpretation of our data.
In conclusion, our study showed that responsiveness to the platelet P2Y12 receptor antagonist 
clopidogrel was related to both CYP2C19 polymorphisms and smoking status. Regarding 
secondary stroke prevention, patients who were current smokers and had a poor genotype 
for clopidogrel metabolism may benefit from clopidogrel treatment similar to that in patients 
who were nonsmokers and had a good genotype. Further larger clinical trials are essential to 
establish whether current smoking may have a significant role in patients who had stroke and 
are undergoing clopidogrel treatment.
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